Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
05:29am, Tuesday, 12'th Dec 2023
Wall Street analysts following Iovance Biotherapeutics set price targets that suggest the stock can triple your money in 2024. Iovance Biotherapeutics is developing cell-based cancer therapies, and th
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
02:22pm, Wednesday, 22'nd Nov 2023
In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny
Why Iovance Biotherapeutics Stock Is Jumping Today
12:00pm, Monday, 20'th Nov 2023
Goldman Sachs initiated a buy recommendation on Iovance with a $12 price target. Many on Wall Street like the stock because of the potential near-term approval of its promising melanoma drug.
Why Iovance Biotherapeutics Stock Is Marching Higher Today
01:03pm, Wednesday, 08'th Nov 2023
Biotech stocks are slumping yet again today. However, Iovance Biotherapeutics is swimming against the current thanks to excitement over its adoptive cell therapy.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
09:01am, Wednesday, 08'th Nov 2023
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
09:47am, Monday, 06'th Nov 2023
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
Iovance Biotherapeutics: Testing Shareholders' Patience
09:12am, Sunday, 22'nd Oct 2023
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on the belief that adoptive cell therapy can effectiv
Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better
02:35pm, Thursday, 19'th Oct 2023
Iovance Biotherapeutics' lifileucel, a tumor infiltrating lymphocyte product, is under FDA review for the treatment of advanced melanoma. The FDA decision on the biologics license application for lifi
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)
10:43pm, Monday, 18'th Sep 2023
Iovance Biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust financials with a cash runway of 13.1 months. Insider buying and strategic ATC investments indicat
Why Shares of Iovance Biotherapeutics Jumped Monday
12:46pm, Monday, 18'th Sep 2023
Iovance's lead therapy lifileucel still has a chance at an early approval to treat advanced melanoma. Lifileucel is also being tested to treat several other types of cancer.
Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today
04:20pm, Friday, 15'th Sep 2023
At first glance, the latest regulatory news is a setback. However, there were more than a few silver linings in this development.
IOVA stock price soared but risk/reward is unfavourable for now
01:18pm, Friday, 15'th Sep 2023
Iovance Biotherapeutics (NASDAQ: IOVA) stock price defied gravity on Friday as investors cheered the latest FDA update about its drug. The shares jumped by more than 15% even as the Nasdaq 100 and S&P
